Overall survival in the Asian subpopulation, including Japanese... | Download Scientific Diagram
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
US regulator scoops Asco with Bristol's lung cancer approval | Evaluate
Forest plots for (a) overall survival and (b) progression-free survival... | Download Scientific Diagram
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients - ScienceDirect
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA | SpringerLink
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 | Journal of Clinical Oncology
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations - Journal of
Defining patient groups for immunotherapy
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. | Semantic
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
Survival in non-small cell lung cancer patients with pre-treated and... | Download Scientific Diagram
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy | Oncology Practice Management
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Rapid Readouts: Three-Year Update From CheckMate 227, Part 1
Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
Checkpoint inhibition in non-small-cell lung cancer: expanding the range of options - memoinOncology